Douglas A Jabs1, Mark L Van Natta2, Jeong Won Pak3, Ronald P Danis3, Peter W Hunt4. 1. Department of Ophthalmology, The Icahn School of Medicine at Mount Sinai, New York, New York; Department of Medicine, The Icahn School of Medicine at Mount Sinai, New York, New York; Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. Electronic address: douglas.jabs@mssm.edu. 2. Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. 3. Department of Ophthalmology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 4. Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, California.
Abstract
PURPOSE: To evaluate the incidence of intermediate-stage age-related macular degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS). DESIGN: Cohort study. METHODS: Patients enrolled in the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) underwent 5- and 10-year follow-up retinal photographs. Intermediate-stage AMD (AREDS stage 3) was determined from these photographs by graders at a centralized Reading Center, using the Age-Related Eye Disease Study-2 grading system. The incidence of AMD in LSOCA was compared with that in the Multi-Ethnic Study of Atherosclerosis (MESA), a Human Immunodeficiency Virus (HIV)-uninfected cohort, which used a similar photographic methodology. RESULTS: The incidence of AMD in LSOCA was 0.65/100 person-years (PY). In a multivariate analysis the only significant risk factor for AMD in LSOCA was smoking; the relative risk vs never-smokers was 3.4 for former smokers (95% confidence interval [CI] 1.3, 9.5; P = .02) and 3.3 for current smokers (95% CI 1.1, 9.7; P = .03). Compared with the MESA cohort, the race/ethnicity- and sex-adjusted risk of AMD in LSOCA was 1.75 (95% CI 1.16, 2.64; P = .008), despite the fact that the mean age of the MESA cohort was 17 years greater than the LSOCA cohort (61 ± 9 years vs 44 ± 8 years). CONCLUSIONS: Patients with AIDS have a 1.75-fold increased race- and sex-adjusted incidence of intermediate-stage AMD compared with that found in an HIV-uninfected cohort. This increased incidence is consistent with the increased incidence of other age-related diseases in antiretroviral-treated, immune-restored, HIV-infected persons when compared with HIV-uninfected persons.
PURPOSE: To evaluate the incidence of intermediate-stage age-related macular degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS). DESIGN: Cohort study. METHODS:Patients enrolled in the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) underwent 5- and 10-year follow-up retinal photographs. Intermediate-stage AMD (AREDS stage 3) was determined from these photographs by graders at a centralized Reading Center, using the Age-Related Eye Disease Study-2 grading system. The incidence of AMD in LSOCA was compared with that in the Multi-Ethnic Study of Atherosclerosis (MESA), a Human Immunodeficiency Virus (HIV)-uninfected cohort, which used a similar photographic methodology. RESULTS: The incidence of AMD in LSOCA was 0.65/100 person-years (PY). In a multivariate analysis the only significant risk factor for AMD in LSOCA was smoking; the relative risk vs never-smokers was 3.4 for former smokers (95% confidence interval [CI] 1.3, 9.5; P = .02) and 3.3 for current smokers (95% CI 1.1, 9.7; P = .03). Compared with the MESA cohort, the race/ethnicity- and sex-adjusted risk of AMD in LSOCA was 1.75 (95% CI 1.16, 2.64; P = .008), despite the fact that the mean age of the MESA cohort was 17 years greater than the LSOCA cohort (61 ± 9 years vs 44 ± 8 years). CONCLUSIONS:Patients with AIDS have a 1.75-fold increased race- and sex-adjusted incidence of intermediate-stage AMD compared with that found in an HIV-uninfected cohort. This increased incidence is consistent with the increased incidence of other age-related diseases in antiretroviral-treated, immune-restored, HIV-infectedpersons when compared with HIV-uninfectedpersons.
Authors: Douglas A Jabs; Mark L Van Natta; Janet T Holbrook; John H Kempen; Curtis L Meinert; Matthew D Davis Journal: Ophthalmology Date: 2007-01-25 Impact factor: 12.079
Authors: C D Holtzer; M A Jacobson; W K Hadley; L Huang; H D Stanley; R Montanti; M K Wong; J D Stansell Journal: AIDS Date: 1998-10-01 Impact factor: 4.177
Authors: Yara T E Lechanteur; Johannes P H van de Ven; Dzenita Smailhodzic; Camiel J F Boon; B Jeroen Klevering; Sascha Fauser; Joannes M M Groenewoud; Gert-Jan van der Wilt; Anneke I den Hollander; Carel B Hoyng Journal: Invest Ophthalmol Vis Sci Date: 2012-08-24 Impact factor: 4.799
Authors: Wan Ling Wong; Xinyi Su; Xiang Li; Chui Ming G Cheung; Ronald Klein; Ching-Yu Cheng; Tien Yin Wong Journal: Lancet Glob Health Date: 2014-01-03 Impact factor: 26.763
Authors: Douglas A Jabs; Mark L Van Natta; Michael F Schneider; Jeong Won Pak; Garrett Trang; Norman G Jones; Jeffrey Milush; Peter W Hunt Journal: AIDS Date: 2022-02-01 Impact factor: 4.632
Authors: Douglas A Jabs; Mark L Van Natta; Jeong Won Pak; Ronald P Danis; Peter W Hunt Journal: Invest Ophthalmol Vis Sci Date: 2018-02-01 Impact factor: 4.799
Authors: Douglas A Jabs; Mark L Van Natta; Garrett Trang; Norman Jones; Jeffrey M Milush; Ryan Cheu; Nichole R Klatt; Jeong Won Pak; Ronald P Danis; Peter W Hunt Journal: Invest Ophthalmol Vis Sci Date: 2019-05-01 Impact factor: 4.799